) The newly-organized Baylor College of Medicine Cancer Center (BCMCC) seeks a P20 Planning Grant with the aim of submitting a P30 application for an NCI Cancer Center Support Grant and being designated a Comprehensive Cancer Center in the next 24-36 months. Our overall Goal is to unify and organize strong, independent scientific programs into a well-functioning Cancer Center. The BCMCC serves Baylor College of Medicine (BCM) and four large teaching hospitals (Ben Taub General Hospital, The Methodist Hospital, Texas Children's Hospital, and the Houston Veterans Administration Hospital) which in 2001 saw 5,000 new cancer cases. BCM has >$50 million in cancer research support with ~$34 million from NCI. Basic, translational, and clinical research are conducted in eight Programs: Breast Cancer (led by C. Kent Osborne, M.D.); Cancer Biology (led by Dennis R. Roop, Ph.D.); Cancer Prevention and Population Sciences (led by Powel H. Brown, M.D., Ph.D.); Cell and Gene Therapy (led by Malcolm K. Brenner, M.D., Ph.D.); Cell Cycle Control, Tumor Suppressors, Viruses, and Oncogenes (led by J. Wade Harper, Ph.D.); Nuclear Receptor Biology (led by Orla M. Conneely, Ph.D.); Prostate Cancer (led by Timothy C. Thompson, Ph.D.); and Pediatric Cancer (led by David G. Poplack, M.D.). Fourteen Shared Resources/Cores support this effort. Michael W. Lieberman, M.D., Ph.D., serves as Center Director and reports directly to the President of BCM. Associate Directors include: Bert W. O'Malley, M.D. (Basic Science); Dr. Osborne (Clinical Science); Dr. Brown (Cancer Prevention, Outreach, and Health Services); and Ms. Barbara G. Cochran (Administration). Governance rests in the hands of an Executive Committee chaired by Dr. Lieberman and composed of the four Associate Directors and seven other BCMCC members. Harold L. Moses, M.D., chairs the External Advisory Committee, and Susan M. Berget, Ph.D., chairs the Internal Advisory Committee. To prepare for a P30 application, we have developed a detailed Strategic Plan with timelines. Our P20 Specific Goals are: 1. To Strengthen Administrative Leadership, Internal Governance, and Institutional Support for the BCMCC; 2. To Increase Interactions among BCMCC Members and Promote Translational Research; 3. To Develop Increased Support for Programs in the Shared Resources/Cores; and 4. To Recruit Additional Faculty to Strengthen Existing Programs and Support Additional Program Development.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Exploratory Grants (P20)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Vembu, Devi
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Baylor College of Medicine
Schools of Medicine
United States
Zip Code
Ittmann, Michael; Huang, Jiaoti; Radaelli, Enrico et al. (2013) Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res 73:2718-36
Ramos, Carlos A; Narala, Neeharika; Vyas, Gayatri M et al. (2013) Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother 36:66-76
Wadhwa, Lalita; Bond, Wesley S; Perlaky, Laszlo et al. (2012) Embryonic retinal tumors in SV40 T-Ag transgenic mice contain CD133+ tumor-initiating cells. Invest Ophthalmol Vis Sci 53:3454-62
Ildefonso, Cristhian J; Bond, Wesley S; Al-Tawashi, Azza R et al. (2012) The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression. J Biol Chem 287:32697-707
Darimipourain, M; Wang, S; Ittmann, M et al. (2011) Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. Prostate Cancer Prostatic Dis 14:279-85
Ildefonso, Cristhian J; Kong, Lingkun; Leen, Ann et al. (2010) Absence of systemic immune response to adenovectors after intraocular administration to children with retinoblastoma. Mol Ther 18:1885-90
Wadhwa, Lalita; Hurwitz, Mary Y; Chevez-Barrios, Patricia et al. (2007) Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res 67:10653-6
Sonpavde, Guru; Okuno, Norihiko; Weiss, Heidi et al. (2007) Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 69:1221-6
Shen, Steven S; Smith, Carolyn L; Hsieh, Jer-Tsong et al. (2006) Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 106:2610-6
Divisova, Jana; Kuiatse, Isere; Lazard, ZaWaunyka et al. (2006) The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 98:315-27

Showing the most recent 10 out of 15 publications